HanAll Pharmaceutical (www.hanall.co.kr) will develop and commercialize three Nautilus Biotech (www.nautilusbiotech.com) products in South Korea: Belerofon® (Interferon alpha); Vitatropin® (human growth hormone); and Eporal™ (erythropoietin).
These three proteins have been designed for extended half-life and oral availability. The technology makes minimal and specific changes to the amino acid sequence to slow the breakdown of the protein in the body, in blood, tissues, or intestine, according to Nautilus.
